|
|
 Previous Article | Table of Contents | Next Article 
Sensitivity of Acute Leukemia Cells to Cytarabine Is a Correlate of Cellular es Nucleoside Transporter Site Content Measured by Flow Cytometry With SAENTA-Fluorescein
Wendy P. Gati,
Alan R.P. Paterson,
Loree M. Larratt,
A. Robert Turner, and
Andrew R. Belch
From the Departments of Pharmacology, Medicine, and Oncology, University of Alberta, and Cross Cancer Institute, Edmonton, Alberta, Canada.
Cytarabine (araC) is converted to araC 5'-triphosphate after entering leukemia cells as a substrate for nucleoside transport processes. This study tested the relationship between araC cytotoxicity, measured in an in vitro tetrazolium dye reduction assay of cell viability, and the cellular abundance of es nucleoside transport elements, assayed by a flow cytometric method that used the es-specific stain, 5-(SAENTA-x8)-fluorescein (5-(Sx8)-F), in cultured leukemia cells and in myeloblasts and lymphoblasts (blasts) from leukemia patients. Cellular es site abundance (Bmax value for 5-(Sx8)-F binding) varied sixfold among nine leukemic myeloblast samples from patients. In cultured OCI/AML-2 myeloblasts and CCRF-CEM T-lymphoblasts, and in fresh leukemic blasts, es sites were fractionally blocked by treatment with graded concentrations of nitrobenzylthioinosine (NBMPR), an inhibitory es site ligand, to simulate the variation in es expression found in leukemic blasts from patients with acute myeloid leukemia. When the cytotoxicity of a single concentration of araC was determined in NBMPR-treated leukemia cells, cell kill correlated closely with the intensity of 5-(Sx8)-F fluorescence (r = .92 to .99), a measure of the cell surface abundance of functional es nucleoside transporter sites. Concentrations of NBMPR that achieved half-maximal reduction (4.3 to 12 nmol/L) of cellular 5-(Sx8)-F fluorescence (measured by flow cytometry) approximated IC50 values (1 to 10 nmol/L) previously found for inhibition by NBMPR of es-mediated nucleoside fluxes in several cell types, supporting the view that 5-(Sx8)-F interacted with the es transporter. The correlation of araC cytotoxicity and the Bmax for 5-(Sx8)-F binding to es sites in cultured leukemia cells and in leukemic blasts from acute leukemia patients (r = .95) suggests that the flow cytometry assay of es capacity may be useful in predicting clinical response to araC.
Blood, Vol. 90 No. 1 (July 1), 1997:
pp. 346-353
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Lopez-Guerra, L. Trigueros-Motos, M. Molina-Arcas, N. Villamor, F. J. Casado, E. Montserrat, E. Campo, D. Colomer, and M. Pastor-Anglada
Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells
Haematologica,
December 1, 2008;
93(12):
1843 - 1851.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Veltkamp, J. H. Beijnen, and J. H.M. Schellens
Prolonged Versus Standard Gemcitabine Infusion: Translation of Molecular Pharmacology to New Treatment Strategy
Oncologist,
March 1, 2008;
13(3):
261 - 276.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Clarke, V. L. Damaraju, J. Zhang, D. Mowles, T. Tackaberry, T. Lang, K. M. Smith, J. D. Young, B. Tomkinson, and C. E. Cass
The Role of Human Nucleoside Transporters in Cellular Uptake of 4'-Thio-beta-D-arabinofuranosylcytosine and beta-D-Arabinosylcytosine
Mol. Pharmacol.,
July 1, 2006;
70(1):
303 - 310.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Takagaki, S. Katsuma, Y. Kaminishi, T. Horio, S. Nakagawa, T. Tanaka, T. Ohgi, and J. Yano
Gene-Expression Profiling Reveals Down-Regulation of Equilibrative Nucleoside Transporter 1 (ENT1) in Ara-C-Resistant CCRF-CEM-Derived Cells
J. Biochem.,
November 1, 2004;
136(5):
733 - 740.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Spratlin, R. Sangha, D. Glubrecht, L. Dabbagh, J. D. Young, C. Dumontet, C. Cass, R. Lai, and J. R. Mackey
The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma
Clin. Cancer Res.,
October 15, 2004;
10(20):
6956 - 6961.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Stam, M. L. den Boer, J. P. P. Meijerink, M. E. G. Ebus, G. J. Peters, P. Noordhuis, G. E. Janka-Schaub, S. A. Armstrong, S. J. Korsmeyer, and R. Pieters
Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia
Blood,
February 15, 2003;
101(4):
1270 - 1276.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Huang, Y. Wang, M. Collins, J. J. Gu, B. S. Mitchell, and L. M. Graves
Inhibition of Nucleoside Transport by p38 MAPK Inhibitors
J. Biol. Chem.,
August 2, 2002;
277(32):
28364 - 28367.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Mackey, L. L. Jennings, M. L. Clarke, C. L. Santos, L. Dabbagh, M. Vsianska, S. L. Koski, R. W. Coupland, S. A. Baldwin, J. D. Young, et al.
Immunohistochemical Variation of Human Equilibrative Nucleoside Transporter 1 Protein in Primary Breast Cancers
Clin. Cancer Res.,
January 1, 2002;
8(1):
110 - 116.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Gourdeau, M. L. Clarke, F. Ouellet, D. Mowles, M. Selner, A. Richard, N. Lee, J. R. Mackey, J. D. Young, J. Jolivet, et al.
Mechanisms of Uptake and Resistance to Troxacitabine, a Novel Deoxycytidine Nucleoside Analogue, in Human Leukemic and Solid Tumor Cell Lines
Cancer Res.,
October 1, 2001;
61(19):
7217 - 7224.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Galmarini, K. Graham, X. Thomas, F. Calvo, P. Rousselot, A. El Jafaari, E. Cros, J. R. Mackey, and C. Dumontet
Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia
Blood,
September 15, 2001;
98(6):
1922 - 1926.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
